ARRY price target of $9.00 implies more than 100% upside to the $4.35 price
Array BioPharma Inc. (NASDAQ: ARRY) could be a double if the analyst call is right. The small molecule biotech signed a pact with Biogen Idec, and it was started as Buy at Cantor Fitzgerald on Thursday. Its price target of $9.00 implies more than 100% upside to the $4.35 price target mid-day Friday.
agreed. and with Merck just taking out Idenix, it could signal the start of buying season for big pharma. There is so much upside with Array, I just can't see them making it more than a year without a buyout.
especially because big pharma has some empty pipelines and full pockets right now.